Navigation Links
part in Medical Technology

Why Do African-Americans Fare Worse With Cancer? Access and Economics Are Only Part of the Story

ANN ARBOR, Mich., July 7 /PRNewswire-USNewswire/ -- An analysis of almost 20,000 patient records from the Southwest Oncology Group's database of clinical trials finds, for the first time, that African-American breast, ovarian, and prostate cancer patients tend to die earlier than patients of oth...

Long-Term Study Evaluates Boosted PREZISTA(R) Vs. Lopinavir/Ritonavir as Part of HIV Combination Therapy in Treatment-Naive Adults

- Ninety-six week ARTEMIS data presented at ICAAC - BRIDGEWATER, N.J., Oct. 26 /PRNewswire/ -- Ninety-six week results presented today from a phase 3, randomized, open-label, ongoing clinical trial showed that 79 percent of treatment-naive HIV-1 infected adults taking PREZISTA(R) 800 mg (t...

Head-to-Head Study Demonstrates Focalin(R) XR Offers Faster and Better Symptom Control than Concerta(R)1 in Early Part of ADHD Patients' Day

- Focalin XR demonstrated better symptom control versus Concerta from 30 minutes to six hours post-dose in primary and secondary endpoints - Only Focalin XR provided onset of effect as early as 30 minutes post-dose - Additional analysis suggests Focalin XR provides comparable efficacy to ...

SurgiLance Safety Lancet Part of Major HIV Testing Initiative in Sub-Saharan Africa

NORCROSS, Ga., April 17 /PRNewswire/ -- The SurgiLance safety lancet, an industry-leading medical safety product manufactured by MediPurpose, has been selected for inclusion in an HIV kit distributed throughout Africa by Nigerian-based Bundi International Diagnostics. Long established in the A...

New 48-Week Efficacy and Safety Data Presented for INTELENCE(TM) (etravirine) as Part of HIV Combination Therapy

BRIDGEWATER, N.J., Feb. 7 /PRNewswire/ -- New data showed that at 48 weeks, significantly more treatment-experienced adults with HIV-1 with documented resistance to non-nucleoside reverse transcriptase inhibitors (NNRTIs) and protease inhibitors (PIs) had an undetectable viral load (defined as...

Genzyme Corporation Selects Diplomat Specialty Pharmacy for 2008 Renagel Medicare Part D Assistance Program

FLINT, Mich., Jan. 17 /PRNewswire/ -- Diplomat Specialty Pharmacy, one of the largest privately owned national specialty pharmacies, announced today that it has entered into an agreement with Genzyme Corporation to administer their 2008 Renagel Medicare Part D Assistance Program. Genzyme is on...

Lack of Medicare Part D Coverage for All Medically Necessary Prescriptions Endangers Older Americans and Those with Chronic Diseases and Disabilities

Coalition of Patient and Consumer Groups calls for Legislative Action to Ensure Access to 'Off-Label' Drug Treatments WASHINGTON, Nov. 20 /PRNewswire-USNewswire/ -- Twenty-six patient, family caregiver and health professional organizations are calling upon Congress to pass legisla...

New Phase 3 Study in Treatment-Naive Adults with HIV Evaluates Efficacy and Safety of Once-Daily PREZISTA(TM)/ritonavir vs. KALETRA(R) as Part of HIV Combination Therapy

- PREZISTA/ritonavir data presented at ICAAC - BRIDGEWATER, N.J., Sept. 18 /PRNewswire/ -- Results from a new ongoing, randomized, controlled, open-label Phase 3 study showed that 84 percent of treatment-naive HIV-1 infected adults taking an investigational dose of PREZISTA(TM) (d...

Data Presented at AACR Meeting Show Peregrine's Bavituximab Equivalent Can Generate Curative Immune Responses as Part of a Vaccine-Like Regimen in Preclinical Models of Aggressive Brain Cancer

--Immunization with a Bavituximab Equivalent and Irradiated Tumor Cells Increased Long-Term Survival to 57% From 0% in Controls in a Preclinical Model of Brain Cancer-- LOS ANGELES and TUSTIN, Calif., April 18, 2007 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. , a clinical stage bioph...

New Phase 3 Study Published in The Lancet Evaluates Efficacy and Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination Therapy in Treatment-Experienced Adults With HIV

BRIDGEWATER, N.J., July 05, 2007 /PRNewswire/ -- Results from the primary analysis of a randomized, controlled, open-label, Phase 3 study showed that 77 percent of treatment-experienced HIV-1 infected adults taking PREZISTA(TM) (darunavir) 600 mg tablets with 100 mg ritonavir (PREZISTA/r) twice da...

Vectibix(R) in Combination With Chemotherapy Significantly Improved Progression-Free Survival in First-Line Metastatic Colorectal Cancer

... The scientific information discussed in this news release relating to new indications for our products is preliminary and investigative and is not part of the labeling approved by the U.S. Food and Drug Administration (FDA) for the products. The products are not approved for the investigational use(s...

Isis Reports Strong Financial Results and Highlights for Second Quarter of 2009

...$656,000 on a line called "Income Tax Benefit" as part of its financial results from continuing operation...ojected annual tax benefit it expects to record as part of its loss from continuing operations in 2009, wh...RNA interference (ssRNAi) technology to Alnylam as part of a new strategic initiative to continue to devel...

NewCardio Announces Master Services Agreement With Dedicated Phase I

...his agreement demonstrates the firm's commitment to the use of technology to improve quality and efficiency." This Master Services Agreement is part of a transition from semi-automated methods to more advanced, higher quality, and more efficient methodologies made possible for the first time throug...

Study Shows Brain Fitness can Save Medicare Billions

...epresents more than $100 billion in potential savings. The report is part of a multi-site trial funded by the National Institutes of Health and known...roups received classroom training in reasoning or memory strategies or took part in computerized brain fitness exercises. Each intervention was based on a ...

Amgen Announces Positive Top-Line Results for Denosumab in Trial for Delay of Skeletal Related Events in Bone Metastases Patients Compared to Zometa(R)

...er, the scientific information discussed in this news release relating to new indications for our products is preliminary and investigative and is not part of the labeling approved by the U.S. Food and Drug Administration (FDA) for the products. The products are not approved for the investigational use(s...

Project Zero Delay Accelerates Drug's Path to Clinical Trial

...e reported their work in the Journal of Clinical Oncology published online on August 3(rd). The joint effort, dubbed Project Zero Delay, is part of a strategic collaboration between the two organizations designed to safely accelerate development of new cancer drugs. In many cases that process t...

British Woman Celebrates a Year of Living Cancer-Free

...ing." The idea behind the new treatment is this: NK cells, which are part of the body's immune system, will target and fight any leukemia cells that ...ber the exact number and doesn't want to reflect too long on such a painful part of her past -- but the cancer returned. Her doctors treated the recu...

FDA Advisory Committee Votes in Favor of SAPHRIS(R) (asenapine) for Acute Bipolar I Disorder and Acute Schizophrenia

...ut these and other factors that may impact the forward-looking statements, see Schering-Plough's Securities and Exchange Commission filings, including part II, Item 1A. "Risk Factors" in the Company's second quarter 2009 10-Q, filed July 24, 2009. ...

Popular Breast Cancer Drug Used with Certain Antidepressants Puts New Jersey Women at Risk

...co Medco Health Solutions, Inc. (NYSE: MHS ) is pioneering the world's most advanced pharmacy (R) and its clinical research and innovations are part of Medco making medicine smarter (TM) for more than 60 million Americans. With more than 20,000 employees dedicated to improving patient healt...

Is Your Hair Taking a Break?

...s, at the first signs of a problem -- whether she notices that her ponytail is smaller than it used to be, she sees more hair in the shower, or if her part is widening. Determining the cause of the hair loss is the first step in treating it and preventing future hair loss." Female-Pattern Hair Los...

NeurogesX Announces Preliminary Results of FDA-Requested Qutenza(TM) Study

...ia (PHN) following pretreatment with an FDA-approved topical anesthetic. As part of the ongoing new drug application (NDA) review, the U.S. Food and Drug Ad...DA's questions relating to the use of an FDA-approved topical anesthetic as part of the Qutenza treatment procedure." About NeurogesX, Inc. ...

Researchers Create First Targeted Knockout Rats Using Zinc Finger Nuclease Technology

... manipulate the genome of living organisms," said Dr. David Smoller, President of Sigma-Aldrich's Research Biotech business unit. "We are proud to be part of the public-private collaboration developing the proof-of-concept for this technique, which we believe will become the standard for the creation of ...

Lexicon's Drug Candidate LX1032 for Carcinoid Syndrome Receives Orphan Drug Designation From EMEA

...ip Brown , M.D., J.D., senior vice president of clinical development at Lexicon. "We are now well positioned to conduct trials of LX1032 in Europe as part of an integrated global development strategy." Lexicon recently initiated a Phase 2 clinical trial of LX1032 in the United States to evaluat...

Lupus Research Institute Highly Encouraged by Benlysta(TM) Trial Results

...nce in finally bringing this potential new lupus treatment to trial," said Dowd. "And we thank the hundreds of people with lupus who enrolled and took part in this important trial. Participation like theirs is critical to finding answers to this illness." The LRI builds the research pipeline and...

Mayo Clinic Study Finds Earliest Evidence of Memory Decline in Middle-Aged People at Genetic Risk for Alzheimer's Disease

...and finding better ways to treat neurological disorders. About Sun Health Research Institute For 23 years, Sun Health Research Institute, part of nonprofit Banner Health, has been a leader nationally and internationally in the effort to find answers to disorders of aging including Alzheimer's...

Schering-Plough Expands Vicriviroc Phase II Study in Treatment-Naive Patients With HIV

...ication within human CD4+ cells, most of which are part of the immune system, vicriviroc is an HIV entry i...for up to 216 weeks of total treatment duration as part of an optimized antiretroviral regimen. AIDS-asso...urities and Exchange Commission filings, including part II, Item 1A. "Risk Factors" in the Company's first...

Results From Drug Trials and New Risk Factors Announced at International Alzheimer's Conference

...to share groundbreaking research and information on the cause, diagnosis, treatment and prevention of Alzheimer's disease and related disorders. As a part of the Association's research program, ICAD 2009 serves as a catalyst for generating new knowledge about dementia and fostering a vital, collegial res...

Music & Medicine: Unique Collaboration Combines Performing Arts and Science

...allerinas on a miniature stage. When she's not performing, though, this University of North Texas (UNT) piano performance doctoral student is part of a collaborative study between the Denton campus and the UNT Health Science Center designed to measure the benefits to a pianist's hands when using ...

University of Michigan Study Shows SEQUENOM's MassARRAY Technology Identifies HPV Infections Missed by Standard Hybridization Test

...ael, Paul A. Oeth, Michael D. Kane, Anthony W. Opipari, Mack T. Ruffin, IV, Linda M. Kalikin, and David M. Kurnit. This work was supported in part by grants from the Mary Kay Ash Charitable Foundation (DMK), SensiGen, LLC (DMK), and the National Cancer Institute of the National Institutes of Heal...

deCODE Discovers Second Common Genetic Risk Factor for Atrial Fibrillation and Stroke

...n which this transformation is being made," said Kari Stefansson, CEO of deCODE. deCODE and the authors wish to thank the participants who took part in this study and made it possible. Financial support for this study was provided by US National Institutes of Health grants HL075266 and U01 HL65962 ...

GNC Unveils Study Results for First and Only Nitric Oxide Product Clinically Proven to Improve Physical Performance at NSCA Conference in Las Vegas

... arginine and 300 mg of grape seed extract, and c. 3.0 gm of micronized arginine and 300 mg of grape seed extract. Amplified Maxertion N.O. is part of a comprehensive line of eight new advanced muscle performance and sports nutrition products from GNC. The entire Pro Performance(R) AMP line was d...

Sirius Genomics Announces New Collaboration with Assistance Publique-Hopitaux de Paris

...king with this internationally acclaimed research group," commented Dr. Brad Popovich, President and CEO of Sirius Genomics. "We are pleased to be a part of this research effort because working with Sirius Genomics will help translate genomic biomarker research in sepsis from the lab bench to the patien...

PTSD Associated With Higher Alzheimer's/Dementia Risk; Moderate Alcohol Consumption May Lower it

...to share groundbreaking research and information on the cause, diagnosis, treatment and prevention of Alzheimer's disease and related disorders. As a part of the Association's research program, ICAD 2009 serves as a catalyst for generating new knowledge about dementia and fostering a vital, collegial res...

Results From Trials of DHA in Alzheimer's Disease and Age-Related Cognitive Decline

...to share groundbreaking research and information on the cause, diagnosis, treatment and prevention of Alzheimer's disease and related disorders. As a part of the Association's research program, ICAD 2009 serves as a catalyst for generating new knowledge about dementia and fostering a vital, collegial res...

Shoulder Surgery Doesn't Prevent Return to Sports

... KEYSTONE, Colo., July 10 /PRNewswire-USNewswire/ -- Replacing a joint in any part of the body often leads to a long recovery process and the possibility of not being able to return to a sport or activity. However, a new study presen...

ASMANEX(R) (Mometasone Furoate Dry Powder Inhaler) Now Approved in Japan for the Treatment of Bronchial Asthma in Adult Patients

...ut these and other factors that may impact the forward-looking statements, see Schering-Plough's Securities and Exchange Commission filings, including part II, Item 1A "Risk Factors" in the Company's first quarter 2009 10-Q, filed May 1, 2009. References: 1. ASMANEX (R) Package Insert. Scher...

FDA Accepts sNDA for Alternative Dosing Regimen for Dacogen(R) (decitabine for injection) to Treat Patients with Myelodysplastic Syndromes (MDS)

...ss," said Cynthia Schwalm, President of Eisai Inc. "This application is one part of a full complement of clinical development programs we have committed for Dacogen and is a vital part of our human health care mission of increasing patient benefits and fulfi...

St. Francis Surgeon Uses Tissue Regeneration Technology to Rebuild Patients' Heart Structures

...rs has three main hospitals in Indianapolis, Beech Grove and Mooresville and operates a medical office building in Plainfield. St. Francis Hospital is part of a network of 13 growing hospital campuses in Indiana and Illinois owned and operated by the Mishawaka-based Sisters of St. Francis Health Services ...

Mayo Clinic Proceedings: A Comprehensive Review of Addiction to Prescription Painkillers Among Patients and Physicians

...ic science research and clinical epidemiology. Mayo Clinic Proceedings is published monthly by Mayo Foundation for Medical Education and Research as part of its commitment to the medical education of physicians. The journal has been published for more than 80 years and has a circulation of 130,000 natio...

Denosumab Demonstrates Superiority Over Zometa(R) in Pivotal Phase 3 Head-to-Head Trial in Breast Cancer Patients With Bone Metastases

...er, the scientific information discussed in this news release relating to new indications for our products is preliminary and investigative and is not part of the labeling approved by the U.S. Food and Drug Administration (FDA) for the products. The products are not approved for the investigational use(s...
Other Tags
(Date:12/17/2014)... , Dec. 16, 2014  Automation is fundamentally ... more evident than at international borders. Over the ... scanners have allowed veteran travelers to self process ... Control (APC) Kiosks at an increasing number of ... According to Maxine Most ...
(Date:12/11/2014)... PAUL, Minn. , Dec. 10, 2014 /PRNewswire/ ... wireless physiologic monitoring, has released a new series ... needs of preclinical toxicology researchers. M series, part ... help toxicologists collect the best possible physiologic data ... Adding functional endpoints to toxicology studies ...
(Date:12/10/2014)... , Dec. 08, 2014 Research and ... the addition of the "Biometrics Market in ... http://photos.prnewswire.com/prnh/20130307/600769 ... projects such as rural banking and upgradation of ... trends witnessed in the market. Besides the aforementioned ...
Breaking Biology News(10 mins):Automated Border Control (ABC) Transforms the Global Travel Experience With More Than 2500 ABC eGates and APC Kiosks Deployed In Airports, Seaports, and Land Borders Worldwide 2New telemetry implants expected to change how large animal toxicology studies are conducted 2Biometrics Market in Japan 2014-2018: Key Vendors are DDS, Fujitsu, Hitachi and NEC 2
(Date:12/22/2014)... Super Saturday, the last Saturday before Christmas, is ... day in the 2014 holiday shopping season. , ... steady pre-Christmas stream of customers, ready to purchase marijuana ... definitely intend to take advantage…of the recreational cannabis as ... enjoying The Grass Station’s holiday sale on vape products. ...
(Date:12/22/2014)... December 22, 2014 In recognition of ... sales to Hero Reward, a local organization that provides ... , Located on a couple hundred acres ... Program offers lodging, world class fishing, hunting, hiking, horseback ... was founded several years ago to support U.S. Service ...
(Date:12/22/2014)... 7,178 small business owners and marketing professionals avoided ... opted instead to join Digital Marketer, an Austin, Texas ... annual “Black Friday Boot Camp”. , ... 5 hour online training event and raised $50,000 in ... Central Texas based charities dedicated to fighting childhood cancer. ...
(Date:12/22/2014)... 2014 NAPW honors ... of the Year. Ms. Foley is recognized with this ... most-recognized networking organization of professional women in the country, ... of Professional Women is a powerfully vibrant networking community ... , “As a nurse, I felt like I made ...
(Date:12/22/2014)... December 22, 2014 At the ... next month in San Antonio, esteemed experts ... dynamics that often stand in the way of ... , This premier faculty development opportunity is ... Leadership, whose mission is to assist nurse educators ...
Breaking Medicine News(10 mins):Health News:Customers at Colorado’s Grass Station Say They’re Enjoying the Experience of Legally Purchasing Marijuana this Year to Give as Christmas Presents to Friends and Family 2Health News:Discount Labels Donates Portion of November Sales to Hero Reward Program 2Health News:Austin Company Digital Marketer Raises 100K to Fight Childhood Cancer 2Health News:Austin Company Digital Marketer Raises 100K to Fight Childhood Cancer 3Health News:National Association of Professional Women Announces Michelle M. Foley, Vice President of Operations of OTTR Chronic Care Solutions, a 2014 Professional Woman of the Year 2Health News:2015 NLN Leadership Conference February 5-7 San Antonio 2Health News:2015 NLN Leadership Conference February 5-7 San Antonio 3
Other Contents